Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06761937

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients - a Phase I Trial

Led by Erasmus Medical Center · Updated on 2025-07-25

30

Participants Needed

1

Research Sites

91 weeks

Total Duration

On this page

Sponsors

E

Erasmus Medical Center

Lead Sponsor

S

Sensius BV

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are studying patients with locally advanced head and neck squamous cell carcinoma (HNSCC) who are treated with radiotherapy (RT) but cannot receive chemotherapy due to age or other health issues. The trial aims to find the recommended dose of thermotherapy added to radiotherapy that is tolerable and does not cause extra side effects. Thermotherapy involves heating the tumor area to improve the effectiveness of radiotherapy, especially since chemotherapy may be too toxic for some patients. Participants will receive thermotherapy once a week alongside standard radiotherapy using a device called the HyperCollar3D, which precisely heats tumors and lymph nodes in the head and neck while avoiding sensitive tissues. The dose of thermotherapy will be gradually increased to find the highest safe dose. In some cases, a temperature probe may be placed in a lymph node to measure the heat during treatment, with separate consent. This is a phase I dose-finding study focusing on safety and tolerability. During the approximately 7-week treatment period and up to 6 months after, researchers will monitor side effects, especially trismus (limited mouth opening), and other toxicities. Patients will undergo regular assessments including mouth opening measurements and patient and doctor-reported outcomes. The trial will determine the recommended dose of thermotherapy to combine with radiotherapy for future studies, while also evaluating local tumor control, disease-free survival, and overall survival.

CONDITIONS

Brief Title

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age �3e= 18 years
  • WHO performance status 0-1
  • Mouth opening before treatment of �3e= 40 mm for women and �3e= 45 mm for men
  • Squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx confirmed by cytology or histology
  • Locally advanced disease (stage III-IV)
  • Planned curative radiotherapy with contraindication for systemic adjuvant treatment
  • Ability to understand study requirements and provide written informed consent
  • Written informed consent obtained
Not Eligible

You will not qualify if you...

  • Previous radiation treatment on the same target volume
  • Any condition or circumstance interfering with compliance to follow-up
  • Presence of pacemakers or clustered metal markers exceeding 2 cm in contact
  • Tumor located below a tracheostomy preventing microwave penetration
  • Shoulder anatomy preventing positioning of the thermotherapy applicator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Approximately 7 weeks

Participants receive standard radiotherapy with additional thermotherapy once a week after a radiotherapy fraction to enhance treatment effectiveness.

Weekly visits for up to 7 weeks

Follow-up

Duration - Up to 6 months after treatment

Participants are monitored for dose limiting toxicities, feasibility, and side effects including trismus for up to 6 months after treatment ends.

Regular follow-up visits during 6 months post-treatment

Trial Site Locations

Total: 1 location

1

Erasmus MC

Rotterdam, South Holland, Netherlands, 3015 CD

Actively Recruiting

Loading map...

Research Team

M

Michiel Kroesen, MD, Dr.

T

Tessa Coenraad, MSc

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Study Evaluating 89Zr Panitumumab for Assessment of Indeterm...

Head and Neck Squamous Cell Carcinoma

Actively Recruiting

1 location

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

3-5 Fraction Stereotactic Body Radiation Therapy for Palliat...

Head and Neck Squamous Cell Carcinoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here